Yahoo9d
Family Medicine physician discusses risks, side effects of GLP-1 medications
CHICAGO — GLP-1, or Glucagon-like peptide-1, medications, similar to Ozemppic and Wegovy, are becoming more accessible, and ...
CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes
Corxel Pharmaceuticals (CORXEL), a leading biotech company committed to bringing innovative science and medicines to underserved patients with cardiometabolic diseases around the world, today ...
Zacks Small Cap Research on MSN2mon
RANI: New Triagonist Data in Weight Loss
The molecule contains GLP-1, glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. It was administered ...
ETF Daily News18d
Structure Therapeutics Selects Lead Oral Small Molecule for Obesity Treatment
The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 ...
Nature20d
Pairing up with GLP-1 to combat obesity
Glucagon-like peptide 1 receptor agonists ... combine the beneficial effects of two or more hormones into a single molecule — are being explored, with a dual GLP-1R/ gastric inhibitory ...
Medscape9d
The Glucagonostatic and Insulinotropic Effects of Glucagon-like Peptide 1 Contribute Equally to its Glucose-lowering Action
Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...